Dr. Soldatov joined the Computational Oncology Service in 2022 as an Assistant Attending. Dr. Soldatov’s research aims to characterize mechanisms of cell fate decisions that coordinate tissue function and quantify how distortions of these mechanisms shape the course of cancer evolution. He develops computational methods to analyze high-throughput measurements at the single-cell resolution, including multi-omics and lineage data. Dr. Soldatov received a PhD in computational biology from the Institute for Information Transmission Problems, Moscow and trained as a postdoctoral fellow at Harvard Medical School with Dr. Peter Kharchenko. Before joining MSKCC, he was an Instructor in Biomedical Informatics at Harvard Medical School. Dr. Soldatov authored many publications in high-ranking journals.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ruslan Soldatov discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.